Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Prices Senior Notes Offering

NEW YORK — PerkinElmer said on Wednesday that it has priced an offering of senior notes totaling $2.3 billion, providing the company with funds to help complete its planned acquisition of BioLegend.

PerkinElmer said it priced an offering of $500 million aggregate principal amount of 0.550 percent senior notes due 2023 at an issue price of 99.964 percent of the principal amount, as well as $800 million aggregate principal amount of 0.85 percent senior notes due 2024 at an issue price of 99.938 percent of the principal amount.

The Waltham, Massachusetts-based company also priced an offering of $500 million aggregate principal amount of 1.9 percent senior notes due 2028 at an issue price of 99.928 percent of the principal amount and $500 million aggregate principal amount of 2.25 percent senior notes due 2031 at an issue price of 99.697 percent of the principal amount.

The issuance of the notes is expected to close on Friday, and the notes will pay interest on a semi-annual basis.

PerkinElmer said the proceeds of the offering will provide some of the money for its $5.25 billion purchase of life science antibodies and reagents provider BioLegend, which was announced in July.

Last month, PerkinElmer entered into a $500 million credit facility to help fund the acquisition. A couple of weeks later, the firm signed an agreement for a $1.5 billion revolving credit facility.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.